You are here

Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
ClinicalTrials.gov_[email protected]
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Painful Diabetic Neuropathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Must have met the inclusion criteria for preceding double-blind study

- Must have received pregabalin or amitriptyline or placebo under double-blind
conditions under double-blind conditions at least during first 3 weeks if double-blind
treatment phase of preceding study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients cannot be included if they experienced a serious adverse event while
participating in preceding double-blind study, which was determined to be related to
the study medication.

NCT00141401
Pfizer
Completed
Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now